Pred. Application No.: 09/928,326 Pred. Filing Date: August 13, 2001

REMARKS

The claims are 16-35 with claims 16 and 35 being independent. Claims 1-15 have been cancelled without prejudice or disclaimer. The specification has been amended to recite the domestic priority data for this application and to insert an Abstract at the end of the application.

Support for claims 16-35 may be found throughout the subject specification. For example, support for claims 16-18 may be found in original claims 1-10 and in the specification at page 2, lines 16-18. Support for claims 19-22 may be found in the specification at page 4, lines 18-19 and at page 5, lines 30-35. Support for claim 23 may be found in the specification at page 4, line 15. Support for claims 24-26 may be found in the specification at page 1, lines 30-35. Support for claims 27-32 may be found in the specification at page 2, lines 16-23. Further support for claim 30 may be found in the specification at page 2, lines 29-32. Support for claims 33-34 may be found in original claim 1 and in the specification at page 2, lines 16-21 and at page 4, line 15. Support for claim 35 may be found in original claim 1 and in the specification at page 2, lines 16-21, at page 3, line 28, and at page 4, line 15. No matter has been added.

For the avoidance of doubt, Applicant notes that, as set forth in the specification, "5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione" (or "Compound (I)") may exist in one of several tautomeric forms, as individual tautomeric forms or as mixtures thereof, all of which are encompassed by the term "Compound (I)" or "5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione". Furthermore, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione contains a chiral atom, and therefore can exist in up to two stereoisomeric forms. The term "5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione" (or "Compound (I)") also encompasses all of these isomeric forms, whether as individual isomers or as mixtures of isomers, including racemates. See the specification at page 2, lines 33-37. Accordingly, when reference is made to "Compound (I)", or to "5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione", or to "5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof", or to "said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione ", all tautomeric and isomeric forms of the compound are intended to be encompassed.

Pred. Application No.: 09/928,326 Pred. Filing Date: August 13, 2001

Additionally for the avoidance of doubt, as set forth in the specification, when reference is made to scalar amounts, including mg amounts and % weight amounts, of "5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form" (or as in the claims: "said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form"), the scalar amount referred to is made in respect of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione per se: for example, 2 mg of Compound (I), or 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, in the form of the maleate salt is that amount of maleate salt which contains 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (not: 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate salt). See the specification, page 3, lines 23-27.

Favorable consideration and early passage to issue are respectfully requested.

Respectfully submitted,

Kathryn L. Sieburth Attorney for Applicants Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\kls\p31831C3\prelim amd